Abstract
Introduction: Web-based cognitive tests have potential for standardized screening in neurodegenerative disorders. We examined accuracy and consistency of cCOG, a computerized cognitive tool, in detecting mild cognitive impairment (MCI) and dementia. Methods: Clinical data of 306 cognitively normal, 120 mild cognitive impairment (MCI), and 69 dementia subjects from three European cohorts were analyzed. Global cognitive score was defined from standard neuropsychological tests and compared to the corresponding estimated score from the cCOG tool containing seven subtasks. The consistency of cCOG was assessed comparing measurements administered in clinical settings and in the home environment. Results: cCOG produced accuracies (receiver operating characteristic-area under the curve [ROC-AUC]) between 0.71 and 0.84 in detecting MCI and 0.86 and 0.94 in detecting dementia when administered at the clinic and at home. The accuracy was comparable to the results of standard neuropsychological tests (AUC 0.69–0.77 MCI/0.91–0.92 dementia). Discussion: cCOG provides a promising tool for detecting MCI and dementia with potential for a cost-effective approach including home-based cognitive assessments.
Original language | English |
---|---|
Article number | e12083 |
Pages (from-to) | e12083 |
Journal | Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring |
Volume | 12 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2020 |
Keywords
- Alzheimer's disease
- clinical decision support
- cognition
- computerized cognitive test
- dementia
- memory
- mild cognitive impairment
- neuropsychology
- web-based cognitive test
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol. 12, No. 1, e12083, 2020, p. e12083.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - cCOG
T2 - A web-based cognitive test tool for detecting neurodegenerative disorders
AU - Rhodius-Meester, Hanneke F.M.
AU - Paajanen, Teemu
AU - Koikkalainen, Juha
AU - Mahdiani, Shadi
AU - Bruun, Marie
AU - Baroni, Marta
AU - Lemstra, Afina W.
AU - Scheltens, Philip
AU - Herukka, Sanna Kaisa
AU - Pikkarainen, Maria
AU - Hall, Anette
AU - Hänninen, Tuomo
AU - Ngandu, Tiia
AU - Kivipelto, Miia
AU - van Gils, Mark
AU - Hasselbalch, Steen Gregers
AU - Mecocci, Patrizia
AU - Remes, Anne
AU - Soininen, Hilkka
AU - van der Flier, Wiesje M.
AU - Lötjönen, Jyrki
N1 - Funding Information: Hanneke FM Rhodius‐Meester performs contract research for Combinostics, all funding is paid to her institution. Teemu Paajanen reports no disclosures. Juha Koikkalainen and Jyrki Lötjönen report that Combinostics owns the following IPR related to the article: 1. J. Koikkalainen and J. Lötjönen. A method for inferring the state of a system, US 7,840,510 B2. 2. J. Lötjönen, J. Koikkalainen, and J. Mattila. State Inference in a heterogeneous system, US 10,372,786 B2. Koikkalainen and Lötjönen are shareholders in Combinostics. Shadi Mahdiani reports no disclosures. Marie Bruun reports no disclosures. Marta Baroni reports no disclosures. Afina W. Lemstra reports no disclosures. Philip Scheltens has received consultancy/speaker fees (paid to the institution) from Biogen, Novartis Cardiology, Genentech, AC Immune. He is PI of studies with Vivoryon, EIP Pharma, IONIS, CogRx, AC Immune, and FUJI‐film/Toyama. Sanna‐Kaisa Herukka reports no disclosures. Maria Pikkarainen reports no disclosures. Anette Hall reports no disclosures. Tuomo Hänninen reports no disclosures. Tiia Ngandu reports no disclosures. Miia Kivipelto has received research support from the Academy of Finland, Swedish Research Council, Joint Program of Neurodegenerative Disorders, Knut and Alice Wallenberg Foundation, Center for Innovative Medicine (CIMED) Stiftelsen Stockholms sjukhem, Konung Gustaf Vs och Drottning Victorias Frimurarstiftelse, Alzheimerfonden, Hjärnfonden, Region Stockholm (ALF and NSV grants). She takes part in the WHO guidelines development group, is a governance committee member of the Global Council on Brain Health, and is on the advisory board of Combinostics and Roche. Mark van Gils reports no disclosures. Steen Gregers Hasselbalch reports no disclosures. Patrizia Mecocci reports no disclosures. Anne Remes reports no disclosures. Hilkka Soininen has received fees as a member of advisory board of ACImmune, MERCK, and Novo Nordisk outside this work. Wiesje M van der Flier performs contract research for Biogen. Research programs of Wiesje van der Flier have been funded by ZonMW, NWO, EU‐FP7, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Gieskes‐Strijbis fonds, Pasman stichting, Boehringer Ingelheim, Piramal Neuroimaging, Combinostics, Roche BV, AVID. She has been an invited speaker at Boehringer Ingelheim and Biogen. All funding is paid to her institution. Funding Information: Research of the Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The clinical database structure was developed with funding from Stichting Dioraphte. For development of the PredictND tool, VTT Technical Research Centre of Finland received funding from European Union's Seventh Framework Programme for research, technological development, and demonstration under grant agreements 601055 (VPH‐DARE@IT), 224328 (PredictAD), and 611005 (PredictND). The FINGER study was funded by Academy of Finland, Finnish Social Insurance Institution, Alzheimer's Research and Prevention Foundation, Juho Vainio Foundation; Swedish Research Council, Alzheimerfonden, Region Stockholm ALF and NSV, Center for Innovative Medicine (CIMED) at Karolinska Institutet, Knut and Alice Wallenberg Foundation, Stiftelsen Stockholms sjukhem; Joint Program of Neurodegenerative Disorders. The collaboration project DAILY (project number LSHM19123‐HSGF) is co‐funded by the PPP Allowance made available by Health‐Holland, Top Sector Life Sciences & Health, to stimulate public‐private partnerships. Wiesje M van der Flier holds the Pasman chair. Funding Information: Research of the Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The clinical database structure was developed with funding from Stichting Dioraphte. For development of the PredictND tool, VTT Technical Research Centre of Finland received funding from European Union's Seventh Framework Programme for research, technological development, and demonstration under grant agreements 601055 (VPH-DARE@IT), 224328 (PredictAD), and 611005 (PredictND). The FINGER study was funded by Academy of Finland, Finnish Social Insurance Institution, Alzheimer's Research and Prevention Foundation, Juho Vainio Foundation; Swedish Research Council, Alzheimerfonden, Region Stockholm ALF and NSV, Center for Innovative Medicine (CIMED) at Karolinska Institutet, Knut and Alice Wallenberg Foundation, Stiftelsen Stockholms sjukhem; Joint Program of Neurodegenerative Disorders. The collaboration project DAILY (project number LSHM19123-HSGF) is co-funded by the PPP Allowance made available by Health-Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships. Wiesje M van der Flier holds the Pasman chair. Publisher Copyright: © 2020 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association
PY - 2020
Y1 - 2020
N2 - Introduction: Web-based cognitive tests have potential for standardized screening in neurodegenerative disorders. We examined accuracy and consistency of cCOG, a computerized cognitive tool, in detecting mild cognitive impairment (MCI) and dementia. Methods: Clinical data of 306 cognitively normal, 120 mild cognitive impairment (MCI), and 69 dementia subjects from three European cohorts were analyzed. Global cognitive score was defined from standard neuropsychological tests and compared to the corresponding estimated score from the cCOG tool containing seven subtasks. The consistency of cCOG was assessed comparing measurements administered in clinical settings and in the home environment. Results: cCOG produced accuracies (receiver operating characteristic-area under the curve [ROC-AUC]) between 0.71 and 0.84 in detecting MCI and 0.86 and 0.94 in detecting dementia when administered at the clinic and at home. The accuracy was comparable to the results of standard neuropsychological tests (AUC 0.69–0.77 MCI/0.91–0.92 dementia). Discussion: cCOG provides a promising tool for detecting MCI and dementia with potential for a cost-effective approach including home-based cognitive assessments.
AB - Introduction: Web-based cognitive tests have potential for standardized screening in neurodegenerative disorders. We examined accuracy and consistency of cCOG, a computerized cognitive tool, in detecting mild cognitive impairment (MCI) and dementia. Methods: Clinical data of 306 cognitively normal, 120 mild cognitive impairment (MCI), and 69 dementia subjects from three European cohorts were analyzed. Global cognitive score was defined from standard neuropsychological tests and compared to the corresponding estimated score from the cCOG tool containing seven subtasks. The consistency of cCOG was assessed comparing measurements administered in clinical settings and in the home environment. Results: cCOG produced accuracies (receiver operating characteristic-area under the curve [ROC-AUC]) between 0.71 and 0.84 in detecting MCI and 0.86 and 0.94 in detecting dementia when administered at the clinic and at home. The accuracy was comparable to the results of standard neuropsychological tests (AUC 0.69–0.77 MCI/0.91–0.92 dementia). Discussion: cCOG provides a promising tool for detecting MCI and dementia with potential for a cost-effective approach including home-based cognitive assessments.
KW - Alzheimer's disease
KW - clinical decision support
KW - cognition
KW - computerized cognitive test
KW - dementia
KW - memory
KW - mild cognitive impairment
KW - neuropsychology
KW - web-based cognitive test
UR - http://www.scopus.com/inward/record.url?scp=85100479471&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/dad2.12083
DO - https://doi.org/10.1002/dad2.12083
M3 - Article
C2 - 32864411
SN - 2352-8729
VL - 12
SP - e12083
JO - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
JF - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
IS - 1
M1 - e12083
ER -